Neumora Therapeutics, Inc. (NMRA)

Over the past six months, Neumora Therapeutics' stock price has been impacted by several events. On May 7, 2026, the stock declined after the company reported its First Quarter 2026 financial results and a business update. On April 6, 2026, the stock increased following the announcement of its participation in the 25th Annual Needham Virtual Healthcare Conference. On March 30, 2026, the stock decreased after the company reported its Fourth Quarter and Full Year 2025 financial results and a business update. On February 17, 2026, several Neumora Therapeutics insiders sold shares to satisfy tax withholding obligations. On February 4, 2026, Neumora Therapeutics participated in the Guggenheim Emerging Outlook: Biotech Summit 2026. On January 5, 2026, the company provided an update on NMRA-511, reporting positive results from its Phase 1b study in Alzheimer's disease agitation. The stock has experienced high volatility, with its price moving typically 17% a week over the past three months. Over the last 12 months, the stock price has increased by 176.10% to 197.4%, with a 52-week range between $0.61 and $3.65.

As a clinical-stage biopharmaceutical company, Neumora Therapeutics, Inc. is primarily focused on research, development, and clinical trials. Traditional demand seasonality is not applicable at this stage, as the company's performance is driven by research milestones, clinical trial progress, and funding.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company's pipeline includes Navacaprant (NMRA-140) for major depressive disorder, NMRA-511 for agitation associated with Alzheimer's disease, M4 muscarinic receptor PAMs (NMRA-861 and NMRA-898) for schizophrenia, NMRA-215 for obesity, NMRA-GCase for Parkinson's Disease, NMRA-CK1d for Amyotrophic Lateral Sclerosis, and NMRA-NMDA for schizophrenia.

Neumora Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States.

Neumora Therapeutics aims to address the global brain disease crisis through a different approach to treatment development. The company focuses on patients, treatment outcomes, and quality of life, supported by translational, clinical, and computational tools for precision medicine in neuroscience. The company's reputation is closely linked to the success of its clinical pipeline and commitment to addressing unmet medical needs in brain diseases.

Neumora Therapeutics, Inc. has a mixed ownership structure, with significant holdings by institutional investors and insiders. Institutions hold approximately 3.20% to 34.06% of the company's stock, with major holders including Softbank Group Corp and Vanguard Group Inc. Insiders hold a substantial portion, approximately 60.09% to 88.37% of the company's stock, with Kristina Burow being the largest individual shareholder.